查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1941484

去识别化医疗资料市场规模、份额和趋势分析报告：按资料类型、应用、最终用途、地区和细分市场预测（2026-2033 年）

De-identified Health Data Market Size, Share & Trends Analysis Report By Type of Data (Genomic Data, Prescription Data, Claims Data, Pharmacogenomic Data, Clinical Data), By Application, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

匿名化医疗数据市场概览

全球去识别化医疗数据市场预计在 2025 年达到 88 亿美元，预计到 2033 年将达到 179.3 亿美元。

预计从 2026 年到 2033 年，该市场将以 9.37% 的复合年增长率成长。推动该市场成长的因素是数据分析在医疗保健领域的日益普及，这使得大规模研究和预测建模能够在不损害患者隐私的情况下进行。

GDPR 和 HIPAA 等法规结构进一步推动了去识别化资料的使用，以实现合规性。人工智慧和机器学习的进步推动了对符合隐私规定的大型资料集的需求，以改善诊断和治疗方法。此外，穿戴式装置、感测器和电子健康记录 (EHR) 产生的数据激增，也扩大了去识别化资料二次利用的范围。

去识别化的健康数据对于临床研究至关重要，因为它使研究人员能够在保护患者隐私的同时分析大规模数据集。这些数据可以识别趋势、评估治疗效果并支持人群健康研究，所有这些都不会洩露个人识别资讯。利用去识别化资料能够帮助研究人员提高研究成果的质量，并推动医学知识和实践的进步。

例如，2023年4月，飞利浦与麻省理工学院医学工程与科学研究所（IMES）合作开发了一套先进的重症监护资料集，旨在推进医疗保健领域的临床研究与开发以及人工智慧应用。该数据集包含来自加护病房患者的匿名数据，并整合了全面的临床信息，以帮助研究人员和教育工作者深入了解重症监护，从而改善患者预后。这项措施将促进人工智慧驱动的医疗解决方案的创新，有助于实现更精准的诊断和个人化治疗。

此外，去识别化技术能够实现不同医疗系统间病患资料的安全共用，促进医疗领域的合作与创新，并推动诊断和治疗技术的进步。它还能提供训练人工智慧系统所需的关键数据，提高医学影像在疾病检测和分析中的准确性和效用。这种方法在保护病患隐私的同时，也有助于改善医疗效果。

例如，2023年12月，专注于将健康数据转化为科研用途的软体公司Inference, Inc.与乔治亚最大的学术医疗系统埃默里医疗保健中心（Emory Healthcare）合作，旨在改善对多样化、汇总且去识别化数据的访问。该计划旨在加速研究进程，改善疾病诊断，并促进新治疗方法的开发。此次合作体现了双方致力于推动医学知识、促进创新以及改善世界各地个人和社区健康福祉的共同承诺。

「与nference的合作使我们加入了一个由顶尖机构组成的联合资料网路，为突破性研究奠定了基础。我们将携手提供全面、数据驱动的见解，以应对当今一些最重要的健康挑战，改善人们的生活，并带来希望。”

乔·德帕，埃默里医疗保健和埃默里大学首席数据和分析官

目录

第一章调查方法和范围

第二章执行摘要

3. 去识别化医疗资料市场变数、趋势和范围

  • 市场谱系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
  • 匿名化医疗数据市场分析工具
    • 产业分析：波特五力模型
    • PESTEL 分析

第四章：匿名化医疗数据市场：按数据类型分類的估算与趋势分析

  • 按资料类型分類的市场份额（2025 年和 2033 年）
  • 全球去识别化医疗数据市场：按数据类型分類的展望
  • 临床数据
  • 基因组数据
  • 患者人口统计学数据
  • 配方数据
  • 计费数据
  • 行为数据
  • 穿戴式装置和感测器数据
  • 调查和患者报告数据
  • 影像资料
  • 检查数据
  • 医院和医疗服务提供者数据
  • 健康社会决定因素 (SDoH) 数据
  • 药物基因组学数据
  • 生物识别数据
  • 营运和财务数据
  • 流行病学数据
  • 医疗利用数据
  • 其他的

第五章：去识别化医疗资料市场：依最终用途分類的估算与趋势分析

  • 按最终用途分類的市场份额（2025 年和 2033 年）
  • 全球去识别化医疗保健数据市场：按最终用途分類的展望
  • 製药公司
  • 生技公司
  • 医疗设备製造商
  • 医疗保健提供者
  • 保险公司/医疗保险公司
  • 研究所
  • 政府机构
  • 其他的

第六章：匿名化医疗数据市场：按应用分類的估算与趋势分析

  • 按应用领域分類的市场份额（2025 年和 2033 年）
  • 全球去识别化医疗数据市场：按应用领域分類的展望
  • 临床研究与测试
  • 公共卫生
  • 精准医疗
  • 卫生经济学与结果研究（HEOR）
  • 人口健康管理
  • 药物发现与开发
  • 提高医疗品质
  • 核保和风险评估
  • 市场进入和商业策略
  • 商业智慧和营运效率
  • 远端医疗和远距监测
  • 病人参与和支持计划
  • 其他的

7. 按地区、估算和趋势分析、资料类型、最终用途和应用分類的去识别化医疗资料市场

  • 2025年及2033年区域市占率分析
  • 区域市场概览
  • 全球市场概览（按地区划分）
  • 市场规模及预测趋势分析，2021-2033年
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争情势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 创新者
  • 供应商概况
    • 主要经销商和通路合作伙伴名单
    • 主要企业市占率分析，2025 年
    • IQVIA
    • Oracle（Cerner Corporation）
    • Optum, Inc.（UnitedHealth Group）
    • ICON plc
    • Veradigm LLC（前身为 Allscripts）
    • IBM
    • Flatiron Health（F. Hoffmann-La Roche Ltd）
    • Premier, Inc.
    • Shaip
    • Komodo Health, Inc.
    • Evidation Health, Inc.
    • Medidata
    • Clarify Health Solutions
    • Satori Cyber Ltd.
Product Code: GVR-4-68040-481-1

De-identified Health Data Market Summary

The global de-identified health data market size was estimated at USD 8.80 billion in 2025 and is projected to reach USD 17.93 billion by 2033, growing at a CAGR of 9.37% from 2026 to 2033. The market is driven by the increasing integration of data analytics in healthcare, which supports large-scale studies and predictive modeling without breaching patient confidentiality.

Regulatory frameworks such as GDPR and HIPAA further incentivize using de-identified data for compliance. Advancements in AI and machine learning amplify the need for extensive, privacy-compliant datasets to improve diagnostic and therapeutic methods. In addition, the surge in data from wearable devices, sensors, and electronic health records (EHRs) has expanded the scope for de-identified data in secondary applications.

De-identified health data is essential for clinical research as it allows researchers to analyze large datasets while protecting patient privacy. This data identifies trends, evaluates treatment effectiveness, and supports population health studies without compromising individual identities. By leveraging de-identified data, researchers can enhance the quality of their findings and facilitate advancements in medical knowledge and practice.

For instance, in April 2023, Philips and the MIT Institute for Medical Engineering and Science (IMES) collaborated to develop an enhanced critical care dataset to advance clinical research and AI applications in healthcare. This dataset includes de-identified data from ICU patients and integrates comprehensive clinical information to support researchers and educators in gaining insights into critical care and improving patient outcomes. The initiative fosters innovation in AI-driven healthcare solutions, contributing to more accurate diagnostics and personalized treatments.

Furthermore, de-identification facilitates collaboration and innovation within the healthcare sector by enabling secure patient data sharing across various healthcare systems, thereby advancing diagnostic and treatment technologies. Moreover, it provides critical data necessary for training AI systems, enhancing the accuracy and relevance of medical imaging for disease detection and analysis. This approach protects patient privacy and drives improvements in healthcare outcomes.

For instance, in December 2023, nference, Inc., a software company focused on transforming healthcare data for research, partnered with Emory Healthcare, Georgia's largest academic health system, to enhance access to diverse, aggregated, de-identified data. This initiative aims to accelerate research efforts, improve disease diagnosis, and facilitate the development of new treatments. The collaboration reflects a mutual commitment to advancing medical knowledge, promoting innovation, and enhancing the health and well-being of individuals and communities globally.

"This collaboration with nference allows us to join a federated data network of leading institutions that will enable ground-breaking research. Together, we can work to improve lives and provide hope, tackling some of the most critical health care challenges of our time while delivering comprehensive, data-driven insights."

Joe Depa, chief data and analytics officer at Emory Healthcare and Emory University

Global De-identified Health Data Market Report Segmentation

This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 - 2033. For this report, Grand View Research has segmented the global de-identified health data market report based on type of data, application, end use, and region:

  • Type of Data Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical Data
  • Genomic Data
  • Patient Demographics
  • Prescription Data
  • Claims Data
  • Behavioral Data
  • Wearable and Sensor Data
  • Survey and Patient-Reported Data
  • Imaging Data
  • Laboratory Data
  • Hospital and Provider Data
  • Social Determinants of Health (SDoH) Data
  • Pharmacogenomic Data
  • Biometric Data
  • Operational and Financial Data
  • Epidemiological Data
  • Healthcare Utilization Data
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical Research and Trials
  • Public Health
  • Precision Medicine
  • Health Economics and Outcomes Research (HEOR)
  • Population Health Management
  • Drug Discovery and Development
  • Healthcare Quality Improvement
  • Insurance Underwriting and Risk Assessment
  • Market Access and Commercial Strategy
  • Business Intelligence and Operational Efficiency
  • Telemedicine and Remote Monitoring
  • Patient Engagement and Support Programs
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical Companies
  • Biotechnology Firms
  • Medical Device Manufacturers
  • Healthcare Providers
  • Insurance Companies/ Healthcare Payers
  • Research Institutions
  • Government Agencies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type of data
    • 1.1.2. End use
    • 1.1.3. Application
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
    • 1.6.3. Volume price analysis (Model 2)
    • 1.6.4. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type of data outlook
    • 2.2.2. End use outlook
    • 2.2.3. Application outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. De-identified Health Data Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
    • 3.2.3. Market Opportunity analysis
  • 3.3. De-identified Health Data Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. De-identified Health Data Market: Type of Data Estimates & Trend Analysis

  • 4.1. Type of Data Market Share, 2025 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global De-identified Health Data Market by Type of Data Outlook
  • 4.4. Clinical Data
    • 4.4.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.5. Genomic Data
    • 4.5.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.6. Patient Demographics
    • 4.6.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.7. Prescription Data
    • 4.7.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.8. Claims Data
    • 4.8.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.9. Behavioral Data
    • 4.9.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.10. Wearable and Sensor Data
    • 4.10.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.11. Survey and Patient-Reported Data
    • 4.11.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.12. Imaging Data
    • 4.12.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.13. Laboratory Data
    • 4.13.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.14. Hospital and Provider Data
    • 4.14.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.15. Social Determinants of Health (SDoH) Data
    • 4.15.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.16. Pharmacogenomic Data
    • 4.16.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.17. Biometric Data
    • 4.17.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.18. Operational and Financial Data
    • 4.18.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.19. Epidemiological Data
    • 4.19.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.20. Healthcare Utilization Data
    • 4.20.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.21. Others
    • 4.21.1. Market estimates and forecast 2021 - 2033 (USD Million)

Chapter 5. De-identified Health Data Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2025 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global De-identified Health Data Market by End Use Outlook
  • 5.4. Pharmaceutical Companies
    • 5.4.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 5.5. Biotechnology Firms
    • 5.5.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 5.6. Medical Device Manufacturers
    • 5.6.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 5.7. Healthcare Providers
    • 5.7.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 5.8. Insurance Companies/ Healthcare Payers
    • 5.8.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 5.9. Research Institutions
    • 5.9.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 5.10. Government Agencies
    • 5.10.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 5.11. Others
    • 5.11.1. Market estimates and forecast 2021 - 2033 (USD Million)

Chapter 6. De-identified Health Data Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2025 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global De-identified Health Data Market by Application Outlook
  • 6.4. Clinical Research and Trials
    • 6.4.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.5. Public Health
    • 6.5.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.6. Precision Medicine
    • 6.6.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.7. Health Economics and Outcomes Research (HEOR)
    • 6.7.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.8. Population Health Management
    • 6.8.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.9. Drug Discovery and Development
    • 6.9.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.10. Healthcare Quality Improvement
    • 6.10.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.11. Insurance Underwriting and Risk Assessment
    • 6.11.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.12. Market Access and Commercial Strategy
    • 6.12.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.13. Business Intelligence and Operational Efficiency
    • 6.13.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.14. Telemedicine and Remote Monitoring
    • 6.14.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.15. Patient Engagement and Support Programs
    • 6.15.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.16. Others
    • 6.16.1. Market estimates and forecast 2021 - 2033 (USD Million)

Chapter 7. De-identified Health Data Market: Regional Estimates & Trend Analysis, By Type of Data, By End use, By Application

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size & Forecasts Trend Analysis, 2021 - 2033:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Mexico market estimates and forecasts 2021 - 2033 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2021 - 2033 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Singapore market estimates and forecasts 2021 - 2033 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Argentina market estimates and forecasts 2021 - 2033 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Innovators
  • 8.4. Vendor Landscape
    • 8.4.1. List of key distributors and channel partners
    • 8.4.2. Key customers
    • 8.4.3. Key company market share analysis, 2025
    • 8.4.4. IQVIA
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Technology Type benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Oracle (Cerner Corporation)
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Technology Type benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Optum, Inc. (UnitedHealth Group)
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Technology Type benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. ICON plc
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Technology Type benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Veradigm LLC (Formerly known as Allscripts)
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Technology Type benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. IBM
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Technology Type benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Flatiron Health (F. Hoffmann-La Roche Ltd)
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Technology Type benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. Premier, Inc.
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Technology Type benchmarking
      • 8.4.11.4. Strategic initiatives
    • 8.4.12. Shaip
      • 8.4.12.1. Company overview
      • 8.4.12.2. Financial performance
      • 8.4.12.3. Technology Type benchmarking
      • 8.4.12.4. Strategic initiatives
    • 8.4.13. Komodo Health, Inc.
      • 8.4.13.1. Company overview
      • 8.4.13.2. Financial performance
      • 8.4.13.3. Technology Type benchmarking
      • 8.4.13.4. Strategic initiatives
    • 8.4.14. Evidation Health, Inc.
      • 8.4.14.1. Company overview
      • 8.4.14.2. Financial performance
      • 8.4.14.3. Technology Type benchmarking
      • 8.4.14.4. Strategic initiatives
    • 8.4.15. Medidata
      • 8.4.15.1. Company overview
      • 8.4.15.2. Financial performance
      • 8.4.15.3. Technology Type benchmarking
      • 8.4.15.4. Strategic initiatives
    • 8.4.16. Clarify Health Solutions
      • 8.4.16.1. Company overview
      • 8.4.16.2. Financial performance
      • 8.4.16.3. Technology Type benchmarking
      • 8.4.16.4. Strategic initiatives
    • 8.4.17. Satori Cyber Ltd.
      • 8.4.17.1. Company overview
      • 8.4.17.2. Financial performance
      • 8.4.17.3. Technology Type benchmarking
      • 8.4.17.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America de-identified health data market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 4 North America de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 5 North America de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 6 U.S. de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 7 U.S. de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 8 U.S. de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 9 Canada de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 10 Canada de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 11 Canada de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 12 Mexico de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 13 Mexico de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 14 Mexico de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 15 Europe de-identified health data market, by region, 2021 - 2033 (USD Million)
  • Table 16 Europe de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 17 Europe de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 18 Europe de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 19 Germany de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 20 Germany de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 21 Germany de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 22 UK de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 23 UK de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 24 UK de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 25 France de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 26 France de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 27 France de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 28 Italy de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 29 Italy de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 30 Italy de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 31 Spain de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 32 Spain de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 33 Spain de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 34 Denmark de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 35 Denmark de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 36 Denmark de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 37 Sweden de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 38 Sweden de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 39 Sweden de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 40 Norway de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 41 Norway de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 42 Norway de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific de-identified health data market, by region, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 45 Asia Pacific de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 47 China de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 48 China de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 49 China de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 50 Japan de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 51 Japan de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 52 Japan de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 53 India de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 54 India de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 55 India de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 56 South Korea de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 57 South Korea de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 58 South Korea de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 59 Australia de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 60 Australia de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 61 Australia de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 62 Thailand de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 63 Thailand de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 64 Thailand de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 65 Latin America de-identified health data market, by region, 2021 - 2033 (USD Million)
  • Table 66 Latin America de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 67 Latin America de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 68 Latin America de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 69 Brazil de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 70 Brazil de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 71 Brazil de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 72 Argentina de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 73 Argentina de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 74 Argentina de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 75 MEA de-identified health data market, by region, 2021 - 2033 (USD Million)
  • Table 76 MEA de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 77 MEA de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 78 MEA de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 79 South Africa de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 80 South Africa de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 81 South Africa de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 82 Saudi Arabia de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 85 UAE de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 86 UAE de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 87 UAE de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 88 Kuwait de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 89 Kuwait de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 90 Kuwait de-identified health data market, by application, 2021 - 2033 (USD Million)

List of Tables

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 De-identified Health Data market: market outlook
  • Fig. 9 De-identified Health Data competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 De-identified Health Data market driver impact
  • Fig. 15 De-identified Health Data market restraint impact
  • Fig. 16 De-identified Health Data market strategic initiatives analysis
  • Fig. 17 De-identified Health Data market: Type of Data movement analysis
  • Fig. 18 De-identified Health Data market: Type of Data outlook and key takeaways
  • Fig. 19 Clinical data market estimates and forecast, 2021 - 2033
  • Fig. 20 Genomic data market estimates and forecast, 2021 - 2033
  • Fig. 21 Patient demographics market estimates and forecast, 2021 - 2033
  • Fig. 22 Prescription data market estimates and forecast, 2021 - 2033
  • Fig. 23 Claims data market estimates and forecast, 2021 - 2033
  • Fig. 24 Behavioral data market estimates and forecast, 2021 - 2033
  • Fig. 25 Wearable and sensor data market estimates and forecast, 2021 - 2033
  • Fig. 26 Survey and patient-reported data market estimates and forecast, 2021 - 2033
  • Fig. 27 Imaging data market estimates and forecast, 2021 - 2033
  • Fig. 28 Laboratory data market estimates and forecast, 2021 - 2033
  • Fig. 29 Hospital and provider data market estimates and forecast, 2021 - 2033
  • Fig. 30 Social determinants of health (SDoH) data market estimates and forecast, 2021 - 2033
  • Fig. 31 Pharmacogenomic data market estimates and forecast, 2021 - 2033
  • Fig. 32 Biometric data market estimates and forecast, 2021 - 2033
  • Fig. 33 Operational and financial data market estimates and forecast, 2021 - 2033
  • Fig. 34 Epidemiological data market estimates and forecast, 2021 - 2033
  • Fig. 35 Healthcare utilization data market estimates and forecast, 2021 - 2033
  • Fig. 36 Others market estimates and forecast, 2021 - 2033
  • Fig. 37 De-identified Health Data market: End use analysis
  • Fig. 38 De-identified Health Data market: End use outlook and key takeaways
  • Fig. 39 Pharmaceutical companies market estimates and forecast, 2021 - 2033
  • Fig. 40 Biotechnology firms market estimates and forecast, 2021 - 2033
  • Fig. 41 Medical device manufacturers market estimates and forecast, 2021 - 2033
  • Fig. 42 Healthcare providers market estimates and forecast, 2021 - 2033
  • Fig. 43 Insurance companies/ Healthcare payers market estimates and forecast, 2021 - 2033
  • Fig. 44 Research institutions market estimates and forecast, 2021 - 2033
  • Fig. 45 Government agencies market estimates and forecast, 2021 - 2033
  • Fig. 46 Others market estimates and forecast, 2021 - 2033
  • Fig. 47 De-identified Health Data market: Application movement analysis
  • Fig. 48 De-identified Health Data market: Application outlook and key takeaways
  • Fig. 49 Clinical research and trials market estimates and forecast, 2021 - 2033
  • Fig. 50 Public health market estimates and forecast, 2021 - 2033
  • Fig. 51 Precision medicine market estimates and forecast, 2021 - 2033
  • Fig. 52 Health economics and outcomes research (HEOR) market estimates and forecast, 2021 - 2033
  • Fig. 53 Population health management market estimates and forecast, 2021 - 2033
  • Fig. 54 Drug discovery and development market estimates and forecast, 2021 - 2033
  • Fig. 55 Healthcare quality improvement market estimates and forecast, 2021 - 2033
  • Fig. 56 Insurance underwriting and risk assessment market estimates and forecast, 2021 - 2033
  • Fig. 57 Market access and commercial strategy market estimates and forecast, 2021 - 2033
  • Fig. 58 Business intelligence and operational efficiency market estimates and forecast, 2021 - 2033
  • Fig. 59 Telemedicine and remote monitoring market estimates and forecast, 2021 - 2033
  • Fig. 60 Patient engagement and support programs market estimates and forecast, 2021 - 2033
  • Fig. 61 Others market estimates and forecast, 2021 - 2033
  • Fig. 62 Global de-identified health data market: Regional movement analysis
  • Fig. 63 Global de-identified health data market: Regional outlook and key takeaways
  • Fig. 64 North America market estimates and forecasts, 2021 - 2033
  • Fig. 65 U.S. key country dynamics
  • Fig. 66 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 67 Canada key country dynamics
  • Fig. 68 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 69 Mexico key country dynamics
  • Fig. 70 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 71 Europe
  • Fig. 72 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 73 UK key country dynamics
  • Fig. 74 UK market estimates and forecasts, 2021 - 2033
  • Fig. 75 Germany key country dynamics
  • Fig. 76 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 77 France key country dynamics
  • Fig. 78 France market estimates and forecasts, 2021 - 2033
  • Fig. 79 Italy key country dynamics
  • Fig. 80 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 81 Spain key country dynamics
  • Fig. 82 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 83 Denmark key country dynamics
  • Fig. 84 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 85 Sweden key country dynamics
  • Fig. 86 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 87 Norway key country dynamics
  • Fig. 88 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 89 Asia Pacific
  • Fig. 90 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 91 China key country dynamics
  • Fig. 92 China market estimates and forecasts, 2021 - 2033
  • Fig. 93 Japan key country dynamics
  • Fig. 94 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 95 India key country dynamics
  • Fig. 96 India market estimates and forecasts, 2021 - 2033
  • Fig. 97 Thailand key country dynamics
  • Fig. 98 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 99 South Korea key country dynamics
  • Fig. 100 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 101 Australia key country dynamics
  • Fig. 102 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 103 Latin America
  • Fig. 104 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 105 Brazil key country dynamics
  • Fig. 106 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 107 Argentina key country dynamics
  • Fig. 108 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 109 Middle East and Africa
  • Fig. 110 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 111 South Africa key country dynamics
  • Fig. 112 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 113 Saudi Arabia key country dynamics
  • Fig. 114 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 115 UAE key country dynamics
  • Fig. 116 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 117 Kuwait key country dynamics
  • Fig. 118 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 119 Market share of key market